
The study developed a population pharmacokinetic (PopPK) model for polymyxin B (PMB) in epithelial lining fluid (ELF) and plasma of critically ill patients with multidrug-resistant gram-negative bacteria (MDR-GNB) pneumonia. It reveals that nebulized PMB and intravenous administration enhance ELF concentration and target attainment probability. Age and albumin levels were key covariates. Pseudomonas aeruginosa requires higher nebulized doses, offering insights to optimize PMB dosing regimens.
Like
Save
Share